Conzip Patent Expiration

Conzip is a drug owned by Cipher Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 11, 2022. Details of Conzip's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858118 Extended release composition containing Tramadol
Apr, 2022

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Conzip's patents.

Given below is the list of recent legal activities going on the following patents of Conzip.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 28 Dec, 2021 US7858118
Payment of Maintenance Fee, 8th Year, Large Entity 04 Jan, 2018 US7858118
Recordation of Patent Grant Mailed 28 Dec, 2010 US7858118
Patent Issue Date Used in PTA Calculation 28 Dec, 2010 US7858118
Issue Notification Mailed 08 Dec, 2010 US7858118
Application Is Considered Ready for Issue 23 Nov, 2010 US7858118
Dispatch to FDC 23 Nov, 2010 US7858118
Issue Fee Payment Verified 12 Nov, 2010 US7858118
Issue Fee Payment Received 12 Nov, 2010 US7858118
Mail Notice of Allowance 01 Oct, 2010 US7858118

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Conzip is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Conzip's family patents as well as insights into ongoing legal events on those patents.

Conzip's Family Patents

Conzip has patent protection in a total of 3 countries. It has a significant patent presence in the US with 75.0% of its patents being US patents. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Conzip.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Conzip's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 11, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Conzip Generic API suppliers:

Tramadol Hydrochloride is the generic name for the brand Conzip. 28 different companies have already filed for the generic of Conzip, with Sun Pharm having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Conzip's generic

Alternative Brands for Conzip

Conzip which is used for managing moderate to moderately severe chronic pain., has several other brand drugs using the same active ingredient (Tramadol Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Athena
Qdolo
Janssen Pharms
Ultram
Kowa Pharms
Seglentis
Purdue Pharma
Ryzolt
Shionogi Inc
Rybix Odt


Apart from brand drugs containing the same ingredient, some generics have also been filed for Tramadol Hydrochloride, Conzip's active ingredient. Check the complete list of approved generic manufacturers for Conzip





About Conzip

Conzip is a drug owned by Cipher Pharmaceuticals Inc. It is used for managing moderate to moderately severe chronic pain. Conzip uses Tramadol Hydrochloride as an active ingredient. Conzip was launched by Cipher Pharms Inc in 2010.

Approval Date:

Conzip was approved by FDA for market use on 07 May, 2010.

Active Ingredient:

Conzip uses Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tramadol Hydrochloride ingredient

Treatment:

Conzip is used for managing moderate to moderately severe chronic pain.

Dosage:

Conzip is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG CAPSULE, EXTENDED RELEASE Prescription ORAL
200MG CAPSULE, EXTENDED RELEASE Prescription ORAL
300MG CAPSULE, EXTENDED RELEASE Prescription ORAL